Recursion Pharmaceuticals, Inc. (RXRX)
4.41
-0.26
(-5.57%)
USD |
NASDAQ |
Jan 20, 15:39
Recursion Pharmaceuticals Research and Development Expense (Quarterly): 107.66M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Hims & Hers Health, Inc. | 40.58M |
| XOMA Royalty Corp. | 0.069M |
| Mirum Pharmaceuticals, Inc. | 42.90M |
| ACADIA Pharmaceuticals, Inc. | 87.83M |
| Amicus Therapeutics, Inc. | 23.42M |